{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:13:52Z","timestamp":1771002832189,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10157-018-1635-6","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T21:56:01Z","timestamp":1535579761000},"page":"258-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients"],"prefix":"10.1007","volume":"23","author":[{"name":"Evocalcet Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Shigematsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"1635_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10157-011-0502-5","volume":"15","author":"H Komaba","year":"2011","unstructured":"Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;15:797\u2013809.","journal-title":"Clin Exp Nephrol"},{"key":"1635_CR2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.V1161141","volume":"11","author":"TB Drueke","year":"2000","unstructured":"Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol. 2000;11:1141\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"1635_CR3","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1359\/jbmr.2002.17.12.2094","volume":"17","author":"G Elder","year":"2002","unstructured":"Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002;17:2094\u2013105.","journal-title":"J Bone Miner Res"},{"key":"1635_CR4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/ki.1995.201","volume":"47","author":"A Torres","year":"1995","unstructured":"Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int. 1995;47:1434\u201342.","journal-title":"Kidney Int"},{"key":"1635_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:14\u20139.","journal-title":"Kidney Int Suppl"},{"key":"1635_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1635_CR7","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"1635_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1681\/ASN.2006070771","volume":"18","author":"KJ Martin","year":"2007","unstructured":"Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol. 2007;18:875\u201385.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"1635_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1744-9987.2008.00631.x","volume":"12","author":"H Komaba","year":"2008","unstructured":"Komaba H, Fukagawa M, Group KRNS. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial. 2008;12(Suppl 1):44\u20139.","journal-title":"Ther Apher Dial"},{"key":"1635_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","volume":"46","author":"C Charytan","year":"2005","unstructured":"Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46:58\u201367.","journal-title":"Am J Kidney Dis"},{"key":"1635_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","volume":"53","author":"M Chonchol","year":"2009","unstructured":"Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53:197\u2013207.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1635_CR12","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10(4):e1001436.","journal-title":"PLoS Med"},{"issue":"4","key":"1635_CR13","doi-asserted-by":"publisher","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","volume":"13","author":"T Kawata","year":"2018","unstructured":"Kawata T, Tokunaga S, Murai M, et al. A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018;13(4):e0195316.","journal-title":"PLoS One"},{"key":"1635_CR14","doi-asserted-by":"crossref","unstructured":"Shigematsu T, Shimazaki R, Fukagawa M, et al. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Adv Clin Pharmacol Appl. 2018","DOI":"10.2147\/CPAA.S171044"},{"key":"1635_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1365-2125.2004.02088.x","volume":"57","author":"N Ohashi","year":"2004","unstructured":"Ohashi N, Uematsu T, Nagashima S, et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol. 2004;57:726\u201334.","journal-title":"Br J Clin Pharmacol"},{"key":"1635_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1744-9987.2008.00556.x","volume":"12","author":"T Akiba","year":"2008","unstructured":"Akiba T, Akizawa T, Tsukamoto Y, et al. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2008;12:117\u201325.","journal-title":"Ther Apher Dial"},{"key":"1635_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5414\/CN108974","volume":"88","author":"K Yokoyama","year":"2017","unstructured":"Yokoyama K, Fukagawa M, Shigematsu T, et al. A 12-week dose-escalating study of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin Nephrol. 2017;88:68\u201378.","journal-title":"Clin Nephrol"},{"key":"1635_CR18","first-page":"272","volume":"33","author":"FJ Borrego-Utiel","year":"2013","unstructured":"Borrego-Utiel FJ, Perez-del Barrio Mdel P, Biechy-Baldan Mdel M, et al. Cinacalcet may prolong the QT interval in patients on haemodialysis with secondary hyperparathyroidism. Nefrologia. 2013;33:272\u20133.","journal-title":"Nefrologia"},{"issue":"7","key":"1635_CR19","first-page":"520","volume":"16","author":"G Temiz","year":"2016","unstructured":"Temiz G, Yalcin AU, Mutluay R, et al. Effects of cinacalcet treatment on QT interval in hemodialysis patients. Anatol J Cardiol. 2016;16(7):520\u20133.","journal-title":"Anatol J Cardiol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1635-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1635-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1635-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T20:48:20Z","timestamp":1661892500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1635-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1635-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"12 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TS has received consulting fees from Kyowa Hakko Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd., and lecture fees from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Kissei Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. MF has received consulting fees from Kyowa Hakko Kirin Co., Ltd. and Ono Pharmaceutical Co., Ltd., and lecture fees from Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin, Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., and grants from Kyowa Hakko Kirin Co., Ltd. and Bayer Yakuhin, Ltd. TA has received consulting fees from Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Fuso Pharmaceutical Industries, Ltd., Japan Tobacco Inc., Ono Pharmaceutical Co., Ltd. and NIPRO Industry, and lecture fees from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Kissei Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. RS is employed by Kyowa Hakko Kirin Co., Ltd., which funded this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the institutional review board of each participating center and conducted in accordance with the Declaration of Helsinki and in compliance with the Pharmaceuticals and Medical Devices Act, Ministerial Ordinance on Good Clinical Practice and its partial amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All individual patients included in the study provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}